Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
39
ADCT Quote, Financials, Valuation and Earnings
Last price:
$3.51
Seasonality move
:
40.45%
Day range:
$3.46 - $3.55
52-week range:
$1.05 - $4.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.40x
P/B ratio:
--
Volume:
549.1K
Avg. volume:
1.6M
1-year change:
65.57%
Market cap:
$434.8M
Revenue:
$70.8M
EPS (TTM):
-$1.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ADCT
ADC Therapeutics SA
|
$19.7M | -- | 8.4% | -- | $8.00 |
|
ACIU
AC Immune SA
|
$509K | -$0.22 | 18.61% | -6.92% | $9.01 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
ALC
Alcon AG
|
$2.7B | $0.83 | 8.35% | 37.98% | $92.10 |
|
CRSP
CRISPR Therapeutics AG
|
$2.6M | -$1.09 | -89.16% | -180.62% | $81.33 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.51 | 29.38% | -70.04% | $400.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ADCT
ADC Therapeutics SA
|
$3.51 | $8.00 | $434.8M | -- | $0.00 | 0% | 5.40x |
|
ACIU
AC Immune SA
|
$3.13 | $9.01 | $314.9M | -- | $0.00 | 0% | 61.04x |
|
ADXN
Addex Therapeutics Ltd.
|
$7.99 | $30.00 | $9.8M | 0.77x | $0.00 | 0% | 36.54x |
|
ALC
Alcon AG
|
$80.38 | $92.10 | $39.5B | 38.20x | $0.34 | 0.42% | 3.93x |
|
CRSP
CRISPR Therapeutics AG
|
$55.08 | $81.33 | $5.2B | -- | $0.00 | 0% | 125.63x |
|
ONC
BeOne Medicines Ltd.
|
$312.39 | $400.06 | $34.6B | 601.10x | $0.00 | 0% | 6.98x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ADCT
ADC Therapeutics SA
|
208.63% | 6.517 | 101.54% | 4.15x |
|
ACIU
AC Immune SA
|
6.95% | 3.999 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 2.172 | 0.5% | 1.91x |
|
ALC
Alcon AG
|
19.18% | -0.654 | 14.32% | 1.14x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ADCT
ADC Therapeutics SA
|
$15.1M | -$30.6M | -148.42% | -- | -186.23% | -$31.7M |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
ALC
Alcon AG
|
$1.5B | $347M | 3.87% | 4.8% | 13.28% | $535M |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
ADC Therapeutics SA vs. Competitors
-
Which has Higher Returns ADCT or ACIU?
AC Immune SA has a net margin of -249.38% compared to ADC Therapeutics SA's net margin of -1688.87%. ADC Therapeutics SA's return on equity of -- beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital ADCTADC Therapeutics SA91.95% -$0.30 $219.3M ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About ADCT or ACIU?
ADC Therapeutics SA has a consensus price target of $8.00, signalling upside risk potential of 127.92%. On the other hand AC Immune SA has an analysts' consensus of $9.01 which suggests that it could grow by 188.23%. Given that AC Immune SA has higher upside potential than ADC Therapeutics SA, analysts believe AC Immune SA is more attractive than ADC Therapeutics SA.
Company Buy Ratings Hold Ratings Sell Ratings ADCTADC Therapeutics SA5 0 0 ACIUAC Immune SA4 0 0 -
Is ADCT or ACIU More Risky?
ADC Therapeutics SA has a beta of 1.887, which suggesting that the stock is 88.684% more volatile than S&P 500. In comparison AC Immune SA has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.243%.
-
Which is a Better Dividend Stock ADCT or ACIU?
ADC Therapeutics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADC Therapeutics SA pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADCT or ACIU?
ADC Therapeutics SA quarterly revenues are $16.4M, which are larger than AC Immune SA quarterly revenues of $1.2M. ADC Therapeutics SA's net income of -$41M is lower than AC Immune SA's net income of -$19.8M. Notably, ADC Therapeutics SA's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADC Therapeutics SA is 5.40x versus 61.04x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADCTADC Therapeutics SA5.40x -- $16.4M -$41M ACIUAC Immune SA61.04x -- $1.2M -$19.8M
-
Which has Higher Returns ADCT or ADXN?
Addex Therapeutics Ltd. has a net margin of -249.38% compared to ADC Therapeutics SA's net margin of -3178.71%. ADC Therapeutics SA's return on equity of -- beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital ADCTADC Therapeutics SA91.95% -$0.30 $219.3M ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About ADCT or ADXN?
ADC Therapeutics SA has a consensus price target of $8.00, signalling upside risk potential of 127.92%. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 275.47%. Given that Addex Therapeutics Ltd. has higher upside potential than ADC Therapeutics SA, analysts believe Addex Therapeutics Ltd. is more attractive than ADC Therapeutics SA.
Company Buy Ratings Hold Ratings Sell Ratings ADCTADC Therapeutics SA5 0 0 ADXNAddex Therapeutics Ltd.0 0 0 -
Is ADCT or ADXN More Risky?
ADC Therapeutics SA has a beta of 1.887, which suggesting that the stock is 88.684% more volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.573, suggesting its more volatile than the S&P 500 by 57.32%.
-
Which is a Better Dividend Stock ADCT or ADXN?
ADC Therapeutics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADC Therapeutics SA pays -- of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADCT or ADXN?
ADC Therapeutics SA quarterly revenues are $16.4M, which are larger than Addex Therapeutics Ltd. quarterly revenues of $62K. ADC Therapeutics SA's net income of -$41M is lower than Addex Therapeutics Ltd.'s net income of -$2M. Notably, ADC Therapeutics SA's price-to-earnings ratio is -- while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADC Therapeutics SA is 5.40x versus 36.54x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADCTADC Therapeutics SA5.40x -- $16.4M -$41M ADXNAddex Therapeutics Ltd.36.54x 0.77x $62K -$2M
-
Which has Higher Returns ADCT or ALC?
Alcon AG has a net margin of -249.38% compared to ADC Therapeutics SA's net margin of 9.07%. ADC Therapeutics SA's return on equity of -- beat Alcon AG's return on equity of 4.8%.
Company Gross Margin Earnings Per Share Invested Capital ADCTADC Therapeutics SA91.95% -$0.30 $219.3M ALCAlcon AG55.78% $0.48 $27.3B -
What do Analysts Say About ADCT or ALC?
ADC Therapeutics SA has a consensus price target of $8.00, signalling upside risk potential of 127.92%. On the other hand Alcon AG has an analysts' consensus of $92.10 which suggests that it could grow by 14.58%. Given that ADC Therapeutics SA has higher upside potential than Alcon AG, analysts believe ADC Therapeutics SA is more attractive than Alcon AG.
Company Buy Ratings Hold Ratings Sell Ratings ADCTADC Therapeutics SA5 0 0 ALCAlcon AG15 7 0 -
Is ADCT or ALC More Risky?
ADC Therapeutics SA has a beta of 1.887, which suggesting that the stock is 88.684% more volatile than S&P 500. In comparison Alcon AG has a beta of 0.967, suggesting its less volatile than the S&P 500 by 3.321%.
-
Which is a Better Dividend Stock ADCT or ALC?
ADC Therapeutics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alcon AG offers a yield of 0.42% to investors and pays a quarterly dividend of $0.34 per share. ADC Therapeutics SA pays -- of its earnings as a dividend. Alcon AG pays out 15.44% of its earnings as a dividend. Alcon AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ADCT or ALC?
ADC Therapeutics SA quarterly revenues are $16.4M, which are smaller than Alcon AG quarterly revenues of $2.6B. ADC Therapeutics SA's net income of -$41M is lower than Alcon AG's net income of $237M. Notably, ADC Therapeutics SA's price-to-earnings ratio is -- while Alcon AG's PE ratio is 38.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADC Therapeutics SA is 5.40x versus 3.93x for Alcon AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADCTADC Therapeutics SA5.40x -- $16.4M -$41M ALCAlcon AG3.93x 38.20x $2.6B $237M
-
Which has Higher Returns ADCT or CRSP?
CRISPR Therapeutics AG has a net margin of -249.38% compared to ADC Therapeutics SA's net margin of -11973.12%. ADC Therapeutics SA's return on equity of -- beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital ADCTADC Therapeutics SA91.95% -$0.30 $219.3M CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About ADCT or CRSP?
ADC Therapeutics SA has a consensus price target of $8.00, signalling upside risk potential of 127.92%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 47.66%. Given that ADC Therapeutics SA has higher upside potential than CRISPR Therapeutics AG, analysts believe ADC Therapeutics SA is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings ADCTADC Therapeutics SA5 0 0 CRSPCRISPR Therapeutics AG12 10 1 -
Is ADCT or CRSP More Risky?
ADC Therapeutics SA has a beta of 1.887, which suggesting that the stock is 88.684% more volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.
-
Which is a Better Dividend Stock ADCT or CRSP?
ADC Therapeutics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADC Therapeutics SA pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADCT or CRSP?
ADC Therapeutics SA quarterly revenues are $16.4M, which are larger than CRISPR Therapeutics AG quarterly revenues of $889K. ADC Therapeutics SA's net income of -$41M is higher than CRISPR Therapeutics AG's net income of -$106.4M. Notably, ADC Therapeutics SA's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADC Therapeutics SA is 5.40x versus 125.63x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADCTADC Therapeutics SA5.40x -- $16.4M -$41M CRSPCRISPR Therapeutics AG125.63x -- $889K -$106.4M
-
Which has Higher Returns ADCT or ONC?
BeOne Medicines Ltd. has a net margin of -249.38% compared to ADC Therapeutics SA's net margin of 8.84%. ADC Therapeutics SA's return on equity of -- beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital ADCTADC Therapeutics SA91.95% -$0.30 $219.3M ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About ADCT or ONC?
ADC Therapeutics SA has a consensus price target of $8.00, signalling upside risk potential of 127.92%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $400.06 which suggests that it could grow by 28.06%. Given that ADC Therapeutics SA has higher upside potential than BeOne Medicines Ltd., analysts believe ADC Therapeutics SA is more attractive than BeOne Medicines Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ADCTADC Therapeutics SA5 0 0 ONCBeOne Medicines Ltd.18 1 1 -
Is ADCT or ONC More Risky?
ADC Therapeutics SA has a beta of 1.887, which suggesting that the stock is 88.684% more volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.
-
Which is a Better Dividend Stock ADCT or ONC?
ADC Therapeutics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADC Therapeutics SA pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADCT or ONC?
ADC Therapeutics SA quarterly revenues are $16.4M, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. ADC Therapeutics SA's net income of -$41M is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, ADC Therapeutics SA's price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 601.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADC Therapeutics SA is 5.40x versus 6.98x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADCTADC Therapeutics SA5.40x -- $16.4M -$41M ONCBeOne Medicines Ltd.6.98x 601.10x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
